Solid biosciences to participate at the svb leerink 11th annual global healthcare conference

Cambridge, mass., feb. 10, 2022 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company focused on advancing meaningful therapies for duchenne muscular dystrophy (duchenne), today announced that joel schneider, phd, chief operating officer, and carl morris, phd, chief scientific officer, will participate in a fireside chat at the svb leerink 11th annual global healthcare conference on thursday, february 17, 2022 at 4:20 pm et.
SLDB Ratings Summary
SLDB Quant Ranking